Thermo Fisher Scientific’s (NYSE:TMO) one of the largest contract drug manufacturing sites in the U.S., has repeatedly been flagged for regulatory violations.
Thermo Fisher’s Greenville facility manufactures around 40 medicines, including Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug Wegovy (semaglutide).
Recently, Stephen’s analyst said that Thermo Fisher’s pharma services assets, especially its contract development and manufacturing organization (CDMO), are well positioned. The company is set to capitalize on growth opportunities in the injectables sector, driven by GLP-1 demand and biologics drug substance production.
Over the past decade, the Greenville plant has been cited for issues related to contamination prevention, including two incidents earlier this ...
